- what commercial prospects for those technologies in medicine?
In 2010, the stem cells market stands on the brink of technological and commercial breakthroughs, our new study explains. For the first time, pharmaceutical companies are beginning to invest significantly in the drive to create new treatments based on embryonic and adult stem cells. As this research gathers pace, with clinical trials commencing, the potential of stem cells in medicine may relatively soon be fulfilled. Results in animals indicate that stem cells may provide treatment options for a range of disorders and restorative applications including multiple sclerosis, diabetes, Parkinson’s disease, Alzheimer’s disease, spinal cord injury, blindness, immune system disorders and cardiovascular disease.
Stem Cells - The Hype and the Hope 2010-2025 provides an analytical overview of this burgeoning sector, with technologies and commercial potential discussed and forecasted. The sector will gather momentum as stem cell therapies start to emerge from the R&D pipeline from this decade onwards. In this report we assess the disease areas in which stem cell therapies are most likely to emerge, with overviews of the commercial and academic research being carried out in subsectors of healthcare. We analyse the short-, medium- and long-term prospects for stem cell breakthroughs in disease areas, providing the information that you require.
Our new report also provides a review of leading companies that currently seek to harness stem cell technologies. The research areas of each company are profiled, with discussion of the approaches being used. Some organisations are developing scalable therapies with allogeneic stem cells, while others investigate personalised treatments using autologous stem cells. Other organisations pursue research in the embryonic stem cells field, which has opened up in the US, with fewer obstacles and greater funding opportunities available since 2009. Some companies already generate revenues from stem cells by carving out market niches in stem cell supply, such as stem cells for drug development and toxicity assays, or services such as stem cell banking in umbilical cord blood. We analyse the main divisions of the market, providing revenue forecasts for 2010 to 2025.
Comprehensive analysis of the global stem cells market
Stem Cells - The Hype and the Hope 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are comprehensive tables and figures, as well as four interviews with experts. The result is a detailed market- and industry-centred study, with analyses and informed opinion to benefit your work.
Why you should buy Stem Cells - The Hype and the Hope 2010-2025
This report gives you the following benefits in particular
• You will receive a comprehensive analysis of the prospects for stem cells from 2010 to 2025, including predicted revenues, growth rates and other data for the overall market and its main divisions
• You will find out where the market is heading - technologically and commercially - from the present onwards, both for the global market and for leading national markets
• You will discover prospects for leading companies and therapy areas, with predictions of where main breakthroughs are likely to come from 2010 to 2025
• You will identify significant R&D developments as well as up-and-coming technologies and products
• You will discover expert opinion from our interview-based survey, with discussion of the present and future of stem cells in medicine
• You will assess the commercial drivers, restraints, competition and opportunities influencing the global stem cell sector.
Our research shows that stem cells hold the potential to change medicine in decades to come, with benefits to healthcare stakeholders starting to appear during our forecast period, 2010 to 2025. We separate the real potential from the wishful thinking in this complex field.
You can obtain this report today
Nobody with an interest in healthcare biotechnology should overlook our new study on stem cells. We predict that revenue streams will commence and increase during our forecast period. With rising demand for novel therapies and many unmet clinical needs remaining, the stem cells industry and market hold potential for high revenues and continuous innovation. Do you want to be aware of those opportunities? You can stay ahead by ordering our new report today.
1. Executive Summary
1.1 Stem Cells Market Review
1.2 Crucial Aspects of the Stem Cells Market
1.3 Aims, Scope and Format of this Report
1.3.1 Speculative Aspects of Assessing the Stem Cell Field
1.3.2 Chapter Outline
1.4 Research and Analysis Methods
2. Stem Cells: An Introduction
2.1 Stem Cells in 2010: Overview of the Sector
2.2 The Basics: What Are Stem Cells?
2.3 Stem Cell Potency
2.3.1 Totipotency
2.3.2 Pluripotency
2.3.3 Multipotency
2.3.4 Oligopotency
2.3.5 Unipotency
2.3.6 Stem Cells and Progenitor Cells
2.4 Embryonic Stem Cells
2.4.1 Abortion Debates, IVF, and Embryonic Stem Cells
2.4.2 Harvesting Human Eggs
2.5 Adult Stem Cells
2.5.1 Sources of Adult Stem Cells
3. Issues Affecting the Stem Cells Market, 2010
3.1 Strengths
3.1.1 Stem Cells Have Great Therapeutic Potential
3.1.2 Stem Cells Could Revolutionise Our Understanding of Disease
3.1.3 Animal Models Yield Impressive Results
3.1.4 Stem Cells Already Have Some Therapeutic Applications
3.1.5 The Stem Cells Field Has Strength in Numbers
3.1.6 Discoveries Are Being Made at a Rapid Rate
3.1.7 Adult Stem Cells: Fewer Ethical Controversies
3.1.8 Many Governments Support Adult Stem Cell Research
3.1.9 Stem Cells Have Proven Uses and Marketability Beyond Their Directly Therapeutic Applications
3.1.10 The Market Offers Multiple Business Models
3.2 Weaknesses
3.2.1 Therapies Take Time
3.2.2 Stem Cells and Cancer
3.2.3 The Safety-First Approach
3.2.4 Embryonic Stem Cell Supply Problems
3.2.5 Business Model Problems with Autologous Therapies
3.2.6 Donor Rejection Risk with Allogeneic Therapies
3.2.7 The Research Field is Fragmented
3.2.8 The IP Minefield
3.2.9 Government Money is Required: Little Venture Capital - Yet
3.2.10 Problems Adapting Pharmaceutical Business Model to Stem Cells
3.3 Opportunities
3.3.1 Therapies: Almost Anything Could Happen
3.3.2 The Attractions of the Stem Cells Market
3.3.3 Asia Harnesses Stem Cells Opportunities
3.3.3.1 China: Favourable Regulations
3.3.3.2 Japan: Liberal hESC Policy
3.3.3.3 Singapore: Advanced and Prominent
3.3.3.4 South Korea: Stem Cells a National Priority
3.3.3.5 India: First Official Research Hub Opened in 2009
3.3.3.6 Israel: at The Forefront
3.3.3.7 Gulf Countries: Funding Stem Cell Research
3.3.4 Adipose Tissue Opportunities for IPSCs
3.3.5 Beyond Pluripotency
3.3.6 Pharmaceutical Laws Do Not Apply to Stem Cell Therapies
3.3.7 Unique Disease Modelling Possibilities With IPS Cells
3.3.8 High Net-Worth Individuals: A Possible Source of Stem Cell Capital
3.3.9 The Opportunity to Get There First
3.3.10 Public Perception of Stem Cells Represents an Opportunity
3.4 Threats
3.4.1 The Risks of the Regulatory Environment
3.4.1.1 North America
3.4.1.2 Europe
3.4.2 Lack of Embryonic Stem Cell Diversity in US Research
3.4.3 Not Everyone Can Succeed in The Stem Cells Market
3.4.4 The Risk of Public Disenchantment
3.4.5 High-Profile Failures in Stem Cell Supply
3.4.6 High-Profile Failures in Stem Cell Therapies
3.4.7 Scare Stories and Perception Problems
3.4.8 Economic Instability
3.4.9 Market Fluidity is a Threat
3.4.10 Are Stem Cells Too Revolutionary for the Existing Pharmaceuticals Model?
4. The Stem Cell Market in 2010
4.1 The Stem Cell Market Was Worth Around $2.8bn in 2009
4.1.1 Where The Money is: Divisions of the Stem Cells Market in 2010
4.2 Stem Cell Therapies
4.2.1 Existing Stem Cell Therapies Market
4.2.2 Diseases Treated With Adult Stem Cells In 2010
4.2.3 Bone Marrow Transplants
4.2.3.1 The Transplant Process
4.2.3.2 The Results
4.2.4. Peripheral Blood Stem Cell Transplants
4.2.5 Cord Blood Stem Cell Transplants
4.2.6 Allogeneic Transplants vs. Autologous Transplants
4.2.6.1 Allogeneic Transplants are Better for Killing Cancer
4.2.6.2 The Problem with Allogenic Transplants: Graft-versus-Host Disease and Host-versus-Graft Disease
4.2.6.3 Saviour-Siblings: Stem Cells from a Sibling, Created or Chosen to be a Saviour
4.2.6.4 UK Cases and Rules on Saviour Siblings
4.2.7 Other Surgery Involving Stem Cells
4.2.8 Osteocel and other Bone Regeneration Products
4.2.9 Stem Cells and Regenerative Medicine
4.2.9.1 Organogenesis
4.2.9.2 Stem Cell Therapeutics
4.2.9.3 CEL-SCI Corporation
4.2.9.4 Osteotech
4.2.9.5 RegeneRx
4.2.9.6 RTI Biologics
4.2.9.7 Biomimetic Therapeutics
4.2.9.8 Fibrocell
4.2.10 Stem Cell Cosmetics
4.2.10.1 Breast Enhancement
4.2.10.2 Topical "Stem Cell Preparations
4.2.11 Unregulated Stem Cells Therapies
4.3 Stem Cell Services
4.3.1 The Market for Stem Cell Services
4.3.2 Some of the Companies in the Stem Cell Services Market
4.3.2.1 Cellular Dynamics International: Cardiomyocyte Technology
4.3.2.2 Fate Therapeutics: Stem Cells for Drug Discovery
4.3.2.3 International Stem Cell Corporation: Parthenogenetic Cell Line Bank
4.3.2.4 Axiogenesis: Research Tools
4.3.2.5 Vitro Biopharma: Longer-Lasting Cell Line Expansion Periods
4.3.2.6 CellCyte Genetics: Expansion Bioreactor
4.3.2.7 MultiCell Technologies: Liver Stem Cell Lines
4.3.2.8 Stemgent: Stem Cell Scientists
4.3.2.9 Regenetech: Stem Cell Expansion Leaders
4.3.2.10 Pfizer/Novocell: Pancreatic Cell Lines
4.3.2.11 Biotime: 200+ Patent Portfolio
4.3.2.12 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction?
4.3.2.13 Stem Cell Innovations (SCI): PluriCells Platform
4.3.2.14 HyClone/Thermo Fisher Scientific: 40 Years of Cell Culture Products
4.3.2.15 Merck/Calibochem/Stem Cell Sciences: Drug Screening Assays
4.3.2.16 Stemride International Limited (SIL) and Reproductive Genetics Institute
4.3.2.17 ES Cell International
Other selected research from the 'Cell therapy' category:
Stem Cell Therapeutics Markets
Stem Cells - The Hype and the Hope 2010-2025